No Data
No Data
Immunic Late-stage Program for Lead Asset to Proceed as Planned
Immunic Phase 3 MS Study Advances Following Positive Recommendation From Independent Committee | NASDAQ:IMUX
GRI Bio GRI Warrants Exercised; Immunic IMUX Phase 3 IDMC Recommendation
Immunic Shares Advance on Positive Outcome From Interim Analysis of Potential MS Treatment
Express News | EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Immunic Analyst Ratings